News | Events | Publications

Tools4Patient Introduces unik-me Platform for Administration of Psychological Questionnaires in Clinical Trials

June 16, 2020

Tools4Patient (T4P) introduces unik-me, our proprietary platform to administer psychological questionnaires to patients in clinical trials.

View

Tools4Patient launches COV-IQ to evaluate the impact of the COVID-19 pandemic on patients in ongoing clinical trials

May 1, 2020

Tools4Patient launches COV-IQ, a new platform aiming to evaluate the impact of COVID-19 on clinical trial patients. COV-IQ aims to quantify the effect of emotional stress, change in trial conduct and changes in social structure on each trial subject.

View

ISCTM Autumn Conference

This society specifically deals with the strategic aspects of clinical trial design, other methodological issues and regulatory issues that confound CNS drug development. Event Date: September 21 – September 25,

View

Does the placebo response need to be considered in clinical trials for COVID-19 vaccines and treatments?

September 22, 2020

The search for drugs to treat and prevent SARS-CoV-2 infection is ongoing, with more than 1200 drugs in the pipeline and more 3,200 clinical trials planned or initiated as of 21 September 2020 (GlobalData). The success of these studies, however, may be at risk due to an invisible threat – the placebo response.

Read More

Frequently asked questions about COV-IQ

September 16, 2020

This webinar aimed to explain the impact of COVID-19 crisis on patient behavior in ongoing clinical trials, introduce the application of COV-IQ technology and describe how it may improve interpretation of clinical trial results. During the webinar, questions from the audience were addressed; the main ones are compiled below.

Read More

Pandemic Stress Will Affect Clinical Trial Response: What Can Industry Do?

July 29, 2020

As one might expect, the life changes are a source of stress, and the data supports this assertion. In fact, a recent analysis by Express Scripts also showed an increase in prescriptions for medications to treat anxiety, depression and insomnia as a result of the pandemic.

Read More

The Placebo response in drug development Part 3: Parkinson’s disease

July 16, 2020

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease characterized by both motor and non-motor features. The disease has a significant clinical impact on patients, families, and caregivers through its progressive degenerative effects on mobility and muscle control.

Read More

Modelling of PNP and OA Placebo Response: Working towards a unique model of the placebo response in chronic pain?

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response negatively impacts the ability to demonstrate superiority of active compounds compared to placebo. The first objective of this analysis was to investigate parameters influencing the placebo response in PNP as a way to control for this major confounding factor.

Type: Scientific Poster

Authors: Samuel Branders, PhD ; Alvaro Pereira, PhD ; Erica Smith, PhD ; Dominique Demolle, PhD.

Date: February 2020

Conference: CNS Clinical Trials and Methodology (ISCTM)

Identification Of Peripheral Neuropathic Pain Sensory Phenotypes Based On Specific Combinations Of Symptoms Identified With The NPSI (Neuropathic Pain Symptom Inventory)

One way to better personalized the treatment of peripheral neuropathic pain (PNP) would be to identify specific sensory phenotypes of patients responding to different classes of drugs.

Type: Scientific Presentation

Authors: Didier Bouhassira(1), Samuel Banders(2), Nadine Attal(1), Dominique Demolle(2) and Alvaro Pereira(2). 1- Inserm 987, Ambroise Pare Hospital, 92100 Boulogne-Billancourt, France 2- Tools4Patient, 50 rue de Bordeaux, boîte 17, 6040 Jumet, Belgium

Date: September 2019

Conference: European Pain Federation (EFIC)

Leveraging Historical Data For High-dimensional Covariate-adaptive Randomization, A Machine Learning Approach.

There is a continuous growth in data collected in clinical trials. Many of those patient’s characteristics are potential confounding factors. Ideally, these factors should be accounted for in the randomization process to balance study arms and reduce the variability of the estimated treatment effect.

Type: Scientific Presentation

Authors: Samuel Branders, PhD; Guillaume Bernard, PhD; Alvaro Pereira, PhD

Date: June 2019

Conference: Promoting Statistical Insight Conference

Learn the importance of considering patient psychological traits, expectations, perception of patient relationship with the trial physician and staff, and social structure in efforts to understand the impact of the COVID-19 pandemic on clinical trials.

Date: June 2020

Erica Smith, VP of Business Development, speaks with Daniel Levin of The Bio Report Podcast about the Placebell©™ method to reduce the impact of the placeb response in drug development”.

Date: June 2019

Learn about how Tools4Patient considers the placebo response of each individual patient in clinical trials as a central part of the Placebell© methodology.

Date: March 2019

Erica Smith, VP of Business Development, discusses the benefits of the Placebell©™ approach in video interview at Biotech Showcase in San Francisco, CA.
Date: January, 2019

Date: January 2019

Sign up to join our regular newsletter.
Be the first to receive the latest innovations and news from Tools4Patient.